An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Harbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...

Dedicated datasets highlight how social determinants of health can be used to improve overall standards of care.

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for ...

Blockchain has numerous potential benefits for healthcare, which is the topic of episode three in the Blockchain in Scotland ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

The NSW government has announced an investment of A$20.7m ($13.39m) aimed at providing access to life-changing therapies.